About the Registry
Who is eligible for the Registry?
All pregnant women ages 18-45 are eligible to enroll in the registry. We are currently seeking both controls and those being treated with one or more of the following atypical antipsychotics:
- Abilify (aripiprazole)
- Aristada (aripiprazole lauroxil)
- Aristada Initio (aripiprazole lauroxil)
- Clozaril (clozapine)
- Fanapt (iloperidone)
- Geodon (ziprasidone)
- Invega (paliperidone)
- Latuda (lurasidone)
- Rexulti (brexpiprazole)
- Risperdal (risperidone)
- Saphris (asenapine)
- Seroquel (quetiapine)
- Zyprexa (olanzapine)
Resources on Atypical Antipsychotics
Required Sponsorship Disclosures:
Current Sponsors: Alkermes, Inc. (2016-Present); Otsuka America Pharmaceutical, Inc. (2008-Present); Sage Therapeutics (2019-Present); Sunovion Pharmaceuticals, Inc. (2011-Present); Teva Pharmaceutical Industries Ltd. (2018-Present).
Past Sponsors: Forest/Actavis (2016-2018, declined to sponsor: 2018-Present), AstraZeneca Pharmaceuticals (2009-2014, declined to sponsor: 2014-Present); Ortho-McNeil-Janssen Pharmaceuticals, Inc (2009-2014, declined to sponsor: 2015-Present); Pfizer, Inc. (2009-2011, declined to sponsor: 2012-Present)
Declined to sponsor: Eli Lilly and Company; Novartis Pharmaceuticals; Vanda Pharmaceuticals Inc.
Funding Information: Manufacturers of psychiatric medications have been approached regarding funding of the National Pregnancy Registry. Regardless of which entities have supported this initiative, all medications in this class are studied. For more information on how to sponsor the Registry, please see the contact information below.